

## Contents

<i>Tables</i>	<i>page</i> ix
<i>Figures</i>	xi
<i>About the Editors</i>	xiii
<i>Contributors</i>	xv
<i>Preface</i>	xxvii
<i>Michael A. Santoro and Thomas M. Gorrie</i>	
<i>Acknowledgments</i>	xxxix
<i>Foreword</i>	xxxiii
<i>Delon Human</i>	
Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry <i>Michael A. Santoro</i>	1
PART I: PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES	
Introduction to Part I <i>Michael A. Santoro</i>	9
1. Drug Research: Between Ethical Demands and Economic Constraints <i>Jürgen Drews</i>	21
2. Emerging International Norms for Clinical Testing: Good Clinical Trial Practice <i>Juhana E. Idänpään-Heikkilä and Sev Fluss</i>	37

vi	<i>Contents</i>	
3.	The Regulatory and Ethical Challenges of Pediatric Research <i>M. Dianne Murphy and Sara F. Goldkind</i>	48
4.	Including Children in Research: Participation or Exploitation? <i>Robert M. Nelson</i>	68
5.	Racial and Ethnic Inclusiveness in Clinical Trials <i>Valentine J. Burroughs</i>	80
6.	The Rights of Patients to Participate in Clinical Research <i>Glenna M. Crooks</i>	97
7.	How Should Government Regulate Stem-Cell Research? Views from a Scientist-Legislator <i>Rush Holt</i>	109
	PART II: MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES	
	Introduction to Part II <i>Michael A. Santoro</i>	127
8.	Ethics and Prescribing: The Clinician's Perspective <i>Charles L. Bardes</i>	136
9.	The Regulation of Prescription Drug Promotion <i>Thomas Abrams</i>	153
10.	Direct-to-Consumer Advertising of Prescription Drugs: A Policy Dilemma <i>Meredith B. Rosenthal and Julie M. Donohue</i>	169
11.	Off-Label Communications and Prescription Drugs <i>Scott D. Danzis</i>	184
12.	The Need for Better Health Information: Advancing the Informed Patient in Europe <i>Don E. Detmer, Peter Singleton, and Scott C. Ratzan</i>	196
13.	Who Should Get Access to Which Drugs? An Ethical Template for Pharmacy Benefits <i>Norman Daniels, James E. Sabin, and J. Russell Teagarden</i>	206
14.	The Application of Cost-Effectiveness and Cost-Benefit Analysis to Pharmaceuticals <i>Joel W. Hay</i>	225

<i>Contents</i>	vii
PART III: PATENTS, PRICING, AND EQUAL ACCESS	
Introduction to Part III <i>Michael A. Santoro</i>	251
15. Intellectual Property Rights, Access to Life-Enhancing Drugs, and Corporate Moral Responsibilities <i>Patricia H. Werhane and Michael E. Gorman</i>	260
16. A Future Agenda for Government–Industry Relations <i>William C. Weldon</i>	282
17. AIDS Activism and the Pharmaceutical Industry <i>Martin Delaney</i>	300
18. The Campaign Against Innovation <i>Sidney Taurel</i>	326
19. Third World Perspectives on Global Pharmaceutical Access <i>James Thuo Gathii</i>	336
20. The Promise of Vaccines and the Influenza Vaccine Shortage of 2004: Public and Private Partnerships <i>Gary R. Noble</i>	352
PART IV: CONCLUDING THOUGHTS: CHARTING A SUSTAINABLE PATH FOR THE TWENTY-FIRST CENTURY	
Introduction to Part IV <i>Michael A. Santoro</i>	363
21. Evolving Approaches to Healthcare Challenges <i>Thomas M. Gorrie</i>	369
22. Property Rights in Crisis: Managers and Rescue <i>Nien-hê Hsieh</i>	379
23. Blurring the Lines: Public and Private Partnerships Addressing Global Health <i>William H. Foegen</i>	386
24. Renegotiating the Grand Bargain: Balancing Prices, Profits, People, and Principles <i>Edward Greg Koski</i>	393
<i>Notes</i>	405
<i>Index</i>	471